Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia

Share :

ASH 2015

5 - 7 Dec 2015
Published: 6 Dec 2015
Views: 2242
Rating:
Save
Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy

Dr Tedeschi presents, at a press conference at ASH 2015, results from the international, randomised phase III study of ibrutinib versus chlorambucil in patients 65 years and older with treatment-naïve chronic lymphocytic leukaemia. 

Read the news story for more information.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )
28 Oct 2024

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India
Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )
9 Oct 2024

Choosing 1st line TKI Wisely in patients with CML

Dr Prashant Mehta - Amrita Hospirtal, Karala, India
Choosing 1st line TKI Wisely in patients with CML ( Dr Prashant Mehta - Amrita Hospirtal, Karala, India )
26 Sep 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg
ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )
15 Sep 2024

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda
Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )
6 Aug 2024

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda
Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )
6 Aug 2024

GIST tumours and soft tissue sarcomas

Dr Atif Hussein - Memorial Cancer Institute, Miami, USA
GIST tumours and soft tissue sarcomas ( Dr Atif Hussein - Memorial Cancer Institute, Miami, USA )
12 Jul 2024

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )
27 Jun 2024

Relapsed refractory multiple myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India
Relapsed refractory multiple myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )
5 Dec 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation